Xanomeline and its Impurities
Xanomeline, a cholinergic agonist, was initially evaluated for the treatment of Alzheimer’s disease and schizophrenia. Reference standards of Xanomeline API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
(E)-3,3'-Bis(hexyloxy)-4,4'-bis(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1l4,1'l4-1,1'-bi(1,2,5-thiadiazolylidene)
(E)-3,3'-Bis(hexyloxy)-4,4'-bis(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1l4,1'l4-1,1'-bi(1,2,5-thiadiazolylidene)
Catalogue No.:PA 24 0111018
CAS :
NA
Molecular Formula : C28H46N6O2S2
Molecular Weight : 562.84
(2R,3R)-2-Hydroxy-3-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)succinic Acid
(2R,3R)-2-Hydroxy-3-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)succinic Acid
Catalogue No.:PA 24 0111039
CAS :
NA
Molecular Formula : C12H15N3O6S
Molecular Weight : 329.33
